# Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

> **NCT05303961** · PHASE1 · COMPLETED · sponsor: **Samjin Pharmaceutical Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SA001 240mg + Rebamipide 200mg or Placebo
- **DRUG:** SA001 480mg or Placebo
- **DRUG:** SA001 710mg + Rebamipide 600mg or Placebo
- **DRUG:** SA001 1,080mg or Placebo
- **DRUG:** SA001 360mg or Placebo
- **DRUG:** SA001 720mg or Placebo
- **DRUG:** SA001 1,080mg or Placebo

## Key facts

- **NCT ID:** NCT05303961
- **Lead sponsor:** Samjin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-07
- **Primary completion:** 2016-11-11
- **Final completion:** 2016-11-11
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303961, "Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05303961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*